Topic - Biogen Inc.

Biogen, Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide. - Source: Wikipedia

Related Stories

FILE - The Biogen Inc., headquarters is pictured on March 11, 2020, in Cambridge, Mass. Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple of years ago. The drugmaker said Wednesday, Jan. 31, 2024 that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of the drug.(AP Photo/Steven Senne, File)

Biogen to shut down its controversial Alzheimer’s drug Aduhelm

By Tom Murphy - Associated Press

The Biogen Inc., headquarters is pictured on March 11, 2020, in Cambridge, Mass. Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday, July 28, 2023, it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year. (AP Photo/Steven Senne, File)

Biogen to bulk up rare disease treatments with $7 billion Reata acquisition

By Tom Murphy - Associated Press

The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s (AP Photo/Steven Senne, File)

Alzheimer’s drug shows promise in early results of study

By Tom Murphy - Associated Press

The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Biogen has agreed, Monday, Sept. 27, 2022, to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, federal prosecutors said. (AP Photo/Steven Senne) **FILE**

Pharmaceutical company Biogen agrees to pay $900 million to settle kickback claims

By Brad Matthews - The Washington Times

The Biogen Inc., headquarters, March 11, 2020, in Cambridge, Mass. Biogen is looking for a new CEO, less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled. The company said Tuesday, May 3, 2022 that current CEO Michel Vounatsos will continue to lead the company until his successor is appointed. (AP Photo/Steven Senne, file)

Change at the top for Biogen after Alzheimer’s drug flops

By Matthew Perrone and Tom Murphy - Associated Press

Officials: 2nd Indiana resident tests positive for COVID-19

Associated Press

FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)

Biogen reanalyzes studies, presses ahead on Alzheimer’s drug

By MARILYNN MARCHIONE - Associated Press

Correction: Puerto Rico-Pharmaceutical Investment story

Associated Press